# GluBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/glubio

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.glubiotx.com
- Total disclosed funding: $92M
- Latest round: Series A (Aug 1, 2022)
- Investors on record: 7

## About

Based in Shanghai, China and founded in 2021, GluBio Therapeutics Inc., trading as GluBio, operates as a drug developer that focuses on the research and development of molecular gel targeted protein degradation drugs. Gang Lu and Liqiang Fu are the founders of the company. 80% of the employees of the core research team have a doctor's degree. The company established an R & D center located in San Diego, California, USA and Zhangjiang, Shanghai. In February 2026, GluBio closed  a strategic investment.

The company focuses on the research and development of small molecule protein antidotes. Its products include molecular glue and PROTAC medicine. The company also develops a multidimensional protein degradation screening platform, an innovative target verification platform, a molecular gel rational design platform, and a proprietary high activity molecular library. The company's products can treat recurrent and refractory hematoma.
The company generates revenue by doing R&D, and providing molecular glue-targeted protein degradation drugs and other related products.
The strategic investment raised in February 2026 will be used to support the company’s innovation in the development of drugs targeting protein degradation using molecular glue, accelerating the development of next-generation molecular glue drugs.

## Funding rounds

- Series A, Aug 1, 2022, $22M — Qiming Venture Partners, Lilly Asia Ventures, Kaitai Capital
- Series A, Feb 28, 2022, $50M — Legend Capital, Qiming Venture Partners, Lilly Asia Ventures, Kaitai Capital, K2VC, E Fund Asset Management, GL Ventures
- Angel, Feb 9, 2021, $20M — Kaitai Capital, K2VC

## Investors

- Kaitai Capital (https://capitalatlas.ai/funds/kaitai-capital) — Angel, Series A
- K2VC (https://capitalatlas.ai/funds/k2vc) — Angel, Series A
- Legend Capital — Series A
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A
- E Fund Asset Management — Series A
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series A